Overview

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of dexlansoprazole delayed-release orally disintegrating (OD) tablets administered on the tongue and swallowed without water.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole